| Biomarker ID | 833 |
| PMID | 22194848 |
| Year | 2011 |
| Biomarker | APOD; C1QTNF3; CD27; CFB; CFH; CLU; CRABP1; DDAH2; FTL; IGSF8; ITIH4l; LGALS3; LYZ; MGAT5; PECAM1; RBP4; RECK; SELENBP1; SLIT2; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | (1.358 fold) Upregulated in PCa [APOD (2.803 fold) ; C1QTNF3 (1.100 fold); CD27 (1.183 fold); CFB (3.231 fold); CFH (1.381 fold); CLU (1.638 fold); CRABP1 (1.477 fold) ; DDAH2 (1.152 fold) ; FTL (1.718 fold); IGSF8 (1.358 fold) ; ITIH4l (1.215 fold) ; LGALS3 (4.121 fold) ; LYZ (2.093 fold) ; MGAT5 (1.112 fold); PECAM1 (2.404 fold) ; RBP4 (1.872 fold); RECK (2.569 fold) ; SELENBP1 (1.327 fold) ; SLIT2 (1.848 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(CFB):-Complement cascade regulation,Alternative complement pathway,Activation of C3 and C5,Complement and coagulation cascades,Complement cascade |
| Experiment | Prostate Cancer Vs Normal controls |
| Type of Biomarker | Diagnostic |
| Cohort | Microarray datasets for prostate, bladder and renal cancer were chosen 19 markers that were upregulated in prostate cancer weer chosen such that they were also upregulated in bladder and renal cancer, |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Microarray |
| Clinical | No |
| Remarks | Genes upregulated in prostate cancer such that they were also upregulated in bladder and/or renal cancer. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | APOD, C1QTNF3, CD27, CFB, CFH, CLU, CRABP1, DDAH2, FTL, IGSF8, ITIH4l, LGALS3, LYZ, MGAT5, PECAM1, RBP4, RECK, SELENBP1, SLIT2 |